Anti-melanin monoclonal antibody

N/A

Report date: 2025/10/20 14:43:50

Base Information

Drug NameAnti-melanin monoclonal antibody

Drug Alias NamePTI6D2PTI-188188RePTI6D2

ClassificationRadiation-emitting products > Nuclides > Rhenium > 188ReRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionIonising radiation emittersAnti-melanin

TargetsMelanin

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAlbert Einstein College Of Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCassava Sciences Inc

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A